as 06-06-2025 4:00pm EST
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Founded: | 2009 | Country: | Israel |
Employees: | N/A | City: | N/A |
Market Cap: | 3.8M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 214.4K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -6.71 | EPS Growth: | N/A |
52 Week Low/High: | $1.71 - $20.27 | Next Earning Date: | 04-10-2025 |
Revenue: | $8,042,999 | Revenue Growth: | 23.17% |
Revenue Growth (this year): | 381.91% | Revenue Growth (next year): | N/A |
RDHL Breaking Stock News: Dive into RDHL Ticker-Specific Updates for Smart Investing
Leasing Life
8 days ago
Offshore Technology
8 days ago
AFP
8 days ago
Footwear News
8 days ago
Business Wire
8 days ago
Investopedia
8 days ago
GlobeNewswire
8 days ago
PR Newswire
8 days ago
The information presented on this page, "RDHL Redhill Biopharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.